Table 4.

Comparison of adverse events between the experimental and control group

Adverse events	Experimental group	Control group	Analysis method	Heterogeneity		Odds Ratio (OR)	95% CI	P-value
No. of patients (n)	No. of patients (n)	I2 (%)	P-value
Nausea, vomiting	452	437	Fixed	37	0.09	0.55	0.41 to 0.74	<0.0001
Nausea, vomiting I+II	292	279	Fixed	0	0.50	0.83	0.59 to 1.16	0.27
Nausea, vomiting III+IV	292	279	Fixed	4	0.41	0.41	0.23 to 0.75	0.003
Diarrhea	395	379	Fixed	0	0.88	0.65	0.46 to 0.90	0.010
Diarrhea I+II	235	221	Fixed	0	0.69	0.84	0.56 to 1.27	0.41
Diarrhea III+IV	235	221	Fixed	0	1.00	0.27	0.10 to 0.75	0.01
Leucopenia	420	429	Fixed	34	0.13	0.62	0.47 to 0.82	0.0008
Leucopenia I+II	250	238	Fixed	0	0.86	0.57	0.39 to 0.83	0.003
Leucopenia III+IV	250	238	Fixed	0	0.77	0.36	0.17 to 0.75	0.007
Thrombocytopenia	178	178	Fixed	0	0.81	0.69	0.44 to 1.11	0.13
Thrombocytopenia I+II	178	178	Fixed	0	0.84	0.70	0.43 to 1.13	0.14
Thrombocytopenia III+IV	178	178	Fixed	0	0.83	0.91	0.39 to 2.14	0.83
Hepatotoxicity	193	193	Random	56	0.04	0.53	0.24 to 1.16	0.11
Hepatotoxicity I+II	193	193	Fixed	26	0.24	0.61	0.38 to 0.97	0.04
Hepatotoxicity III+IV	193	193	Fixed	0	0.70	0.14	0.02 to 0.81	0.03
Nephrotoxicity	117	107	Fixed	0	0.77	0.56	0.16 to 1.95	0.36
Nephrotoxicity I+II	117	107	Fixed	0	0.54	0.63	0.16 to 2.46	0.51
Nephrotoxicity III+IV	117	107	Fixed			0.32	0.01 to 8.24	0.49
Oral mucositis	235	233	Random	64	0.010	0.62	0.28 to 1.34	0.22
Oral mucositis I+II	179	178	Fixed	44	0.13	1.08	0.68 to 1.72	0.74
Oral mucositis III+IV	179	178	Fixed	0	0.58	0.54	0.15 to 1.96	0.35
Alopecia	133	130	Fixed	0	0.58	0.61	0.24 to 1.56	0.30
Alopecia I+II	133	130	Fixed	0	0.93	0.93	0.48 to 1.81	0.83
Alopecia III+IV	133	130	Fixed	0	0.97	0.72	0.30 to 1.75	0.47
Hand foot syndrome	334	356	Fixed	0	0.52	0.57	0.41 to 0.79	0.0007
Hand foot syndrome I+II	92	92	Fixed	12	0.32	0.64	0.33 to 1.24	0.18
Hand foot syndrome III+IV	92	92	Fixed			0.48	0.04 to 5.63	0.56
Anemia	292	291	Fixed	0	0.91	0.69	0.48 to 0.99	0.05
Anemia I+II	186	187	Fixed	0	0.65	0.92	0.60 to 1.42	0.71
Anemia III+IV	186	187	Fixed	0	0.87	0.34	0.12 to 0.96	0.04
Gastrointestinal adverse effects	277	295	Random	57	0.04	0.56	0.32 to 1.00	0.05
Gastrointestinal adverse effects I+II	71	72	Fixed	0	0.75	0.71	0.35 to 1.42	0.33
Gastrointestinal adverse effects III+IV	71	72	Fixed			0.39	0.09 to 1.60	0.19
Peripheral neurotoxicity	265	263	Fixed	0	0.59	0.32	0.20 to 0.50	<0.00001
Peripheral neurotoxicity I+II	103	104	Fixed	29	0.24	0.52	0.26 to 1.03	0.06
Peripheral neurotoxicity III+IV	103	104	Fixed	0	0.53	0.58	0.21 to 1.63	0.30
Neutropenia	55	55	Fixed	0	0.98	0.45	0.14 to 1.42	0.17
Neutropenia I+II	55	55	Fixed	0	0.35	0.93	0.44 to 1.96	0.85
Neutropenia III+IV	55	55	Fixed	0	0.40	0.73	0.34 to 1.59	0.43
Myelosuppression	94	90	Random	80	0.03	0.38	0.08 to 1.84	0.23
Myelosuppression I+II	58	58	Fixed			1.09	0.48 to 2.49	0.83
Myelosuppression III+IV	58	58	Fixed			0.24	0.03 to 2.19	0.20

Notes: Control group, chemotherapy alone group; Experimental group, chemotherapy and cinobufotalin combined group.